항암 치료를 받는 환자의 치과적 고려사항 = Dental Considerations for Patients Undergoing Chemotherapy

국문 초록 (Abstract)

암 치료의 발전으로 많은 종류의 암들에서 생존율이 향상되었지만 이러한 치료들은 구강 내 합병증 등 여러 가지 부작용을 유발할 수 있고[1], 항암 치료를 받는 환자의 구강 합병증은 잠재적으로 전신적인 영향을 미칠 수 있다. 그러나 정립된 지침에 따라 철저한 구강 검사와 치과치료를 시행하면 이와 같은 문제점들이 발생하기 전에 잠재적인 병인을 해결할 수 있다[2]. 치료의 목적과는 상관없이 방사선치료와 항암 치료는 단독으로 또는 병용하여 사용될 때 구강 구조와 인접 조직을 심각하게 손상시킬 수 있고, 건강한 사람의 점막은 일상적인 외상을 견뎌 내지만 항암 치료를 받은 점막은 궤양 및 이차 감염에 취약하게 된다. 따라서 항암 치료는 구강건조증(drymouth, xerostomia), 점막염(mucositis), 골괴사, 충치, 기회 감염, 연하장애, 미각 이상, 타액 감소증과 같이 많은 부작용들을 초래할 수 있다[3]. 이렇게 구강에서 발생한 부작용들은 환자의 삶의 질뿐 아니라 항암 치료의 결과에도 영향을 미칠 수 있으므로, 본 고에서는 항암 치료 환자의 치과적인 고려사항들에 대해 살펴보고 치과적 문제점들을 해결할 수 있는 방법들 및 치과와의 협진 시에 고려해야할 사항들에 대해 생각해 보고자 한다.

다국어 초록 (Multilingual Abstract)

Even with the advances in chemotherapeutic procedures and agents, chemotherapy may cause certain side effects that impair patients’ quality of life. Cancer treatment can lead to various other side effects, such as xerostomia, mucositis, dental caries, opportunistic infections, hypogeusia, dysgeusia, hyposalivation, and medication-related osteonecrosis of the jaw. The oral cavity is a common site of discomfort and pain caused by chemotherapy. In this paper, I will discuss the dental considerations for patients undergoing chemotherapy and cover how to address dental problems and what to consider when consulting with dentists.

참고문헌 (Reference)

• 1 이연희, "Xerostomia and halitosis : a review and current concepts" 55 : 640-656, 2017
• 2 Villa A, "World Workshop on Oral Medicine VI : a systematic review of medication-induced salivary gland dysfunction" 22 : 365-382, 2016
• 3 Epstein JB, "The role of salivary function in modulating chemotherapy-induced oropharyngeal mucositis : a review of the literature" 94 : 39-44, 2002
• 4 Lalla RV, "The MASCC textbook of cancer supportive care and survivorship" Springer 409-420, 2018
• 5 Rolston KV, "The Infectious Diseases Society of America 2002 guidelines for the use of antimicrobial agents in patients with cancer and neutropenia : salient features and comments" 39 (39): S44-S48, 2004
• 6 Vistoso Monreal A, "Salivary gland dysfunction secondary to cancer treatment" 3 : 907778-, 2022
• 7 Napeñas JJ, "Relationship between mucositis and changes in oral microflora during cancer chemotherapy" 103 : 48-59, 2007
• 8 Pinto VL, "Prevalence of xerostomia in women during breast cancer chemotherapy" 73 (73): e20190785-, 2020
• 9 Dawes C, "Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man" 66 : 648-653, 1987
• 10 Sonis ST, "Perspectives on cancer therapy-induced mucosal injury:pathogenesis, measurement, epidemiology, and consequences for patients" 100 (100): 1995-2025, 2004
• 11 Raber-Durlacher JE, "Periodontal infection in cancer patients treated with high-dose chemotherapy" 10 : 466-473, 2002
• 12 Epstein JB, "Periodontal disease and periodontal management in patients with cancer" 37 : 613-619, 2001
• 13 Marx RE, "Pamidronate(Aredia)and zoledronate(Zometa)induced avascular necrosis of the jaws : a growing epidemic" 61 : 1115-1117, 2003
• 14 Chaveli-López B, "Oral toxicity produced by chemotherapy : a systematic review" 6 : e81-e90, 2014
• 15 Xu Y, "Oral side effects of immune checkpoint inhibitor therapy(ICIT) : an analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women’s Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019" 127 : 1796-1804, 2021
• 16 Al-Ansari S, "Oral mucositis induced by anticancer therapies" 2 : 202-211, 2015
• 17 유미현, "Oral mucosal lesions" 55 : 468-480, 2017
• 18 National Cancer Institute, "Oral complications of cacer terapies (PDQ®)-patient version"
• 19 Parra-Rojas S, "Oral complications and management strategies for cancer patients : principles of supportive oncology in dentistry" 26 : 391-399, 2024
• 20 Elad S, "Oral candidiasis prevention in transplantation patients : a comparative study" 20 : 318-824, 2006
• 21 Marx RE, "Oral bisphosphonateinduced osteonecrosis : risk factors, prediction of risk using serum CTX testing, prevention, and treatment" 65 : 2397-2410, 2007
• 22 Chambers MS, "Oral and dental management of the cancer patient : prevention and treatment of complications" 3 : 168-175, 1995
• 23 McCaul LK, "Oral and dental management for head and neck cancer patients treated by chemotherapy and radiotherapy" 39 : 135-138, 2012
• 24 Bensinger W, "NCCN Task Force Report. prevention and management of mucositis in cancer care" 6 (6): S1-S21, 2008
• 25 김진우 ; 곽미경 ; 한정준 ; 이성탁 ; 김하영 ; 김세화 ; 정준호 ; 이정근 ; 이영균 ; 권용대 ; 김덕윤, "Medication related osteonecrosis of the jaw : 2021 position statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons" 28 : 279-296, 2021
• 26 김경민 ; 김덕윤 ; 이유미 ; 권용대 ; 권대근 ; 이정근, "Medication related osteonecrosis of the jaw : 2015position statement of the Korean Society for Bone and mineral research and the Korean Association of Oral and Maxillofacial Surgeons" 22 : 151-165, 2015
• 27 Lalla RV, "Management of oral mucositis in patients who have cancer" 52 : 61-77, 2008
• 28 Lerman MA, "Management of oral infections in cancer patients" 52 : 129-153, 2008
• 29 최정임 ; 유태민, "MRONJ(medication-related osteonecrosis of the jaw)-2022 Update : Review" 12 : 15-25, 2023
• 30 Lalla RV, "MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy" 120 : 1453-1461, 2014
• 31 Ng TL, "Long-term impact of bone-modifying agents for the treatment of bone metastases : a systematic review" 29 : 925-943, 2021
• 32 Watts NB, "Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 years" 104 : 2443-2452, 2019
• 33 Worthington HV, "Interventions for treating oral candidiasis for patients with cancer receiving treatment" 2010 : CD001972-, 2010
• 34 Mahood DJ, "Inhibition of fluorouracil-induced stomatitis by oral cryotherapy" 9 : 449-452, 1991
• 35 Saad F, "Incidence, risk factors, and outcomes of osteonecrosis of the jaw : integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases" 23 : 1341-1347, 2012
• 36 Tennis P, "Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis" 21 : 810-817, 2012
• 37 Epstein JB, "Fluconazole mouthrinses for oral candidiasis in postirradiation, transplant, and other patients" 93 : 671-675, 2002
• 38 Jones JA, "Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer" 14 : 505-515, 2006
• 39 Bondestam O, "Effect of chlorhexidine gel treatment on the prevalence of mutans streptococci and lactobacilli in patients with impaired salivary secretion rate" 16 : 123-127, 1996
• 40 박문수, "Dry mouth and halitosis management" 58 : 751-759, 2020
• 41 Khan AA, "Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus" 30 : 3-23, 2015
• 42 Brennan MT, "Dental treatment planning and management in the patient who has cancer" 52 : 19-37, 2008
• 43 Chaveli López B, "Dental treatment considerations in the chemotherapy patient" 3 : e31-e42, 2011
• 44 Barclay SC, "Current practice in dental oncology in the U. K" 37 : 555-558, 2010
• 45 Vissink A, "Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients : successes and barriers" 78 : 983-991, 2010
• 46 박용 ; 김열홍, "Chemotherapy related oral and gastrointestinal mucositis" 52 : 897-906, 2009
• 47 Lalla RV, "Chemotherapy or radiation-induced oral mucositis" 58 : 341-349, 2014
• 48 Poulopoulos A, "Chemotherapy : oral side effects and dental interventions-a review of the literature" 1 : 35-49, 2017
• 49 Li XS, "Candida albicans cell wall ssa proteins bind and facilitate import of salivary histatin 5 required for toxicity" 281 : 22453-22463, 2006
• 50 Ravasco P, "Aspects of taste and compliance in patients with cancer" 9 (9): S84-S91, 2005
• 51 Yoneda T, "Antiresorptive agent-related osteonecrosis of the jaw: position paper 2017 of the Japanese Allied Committee on osteonecrosis of the jaw" 35 : 6-19, 2017
• 52 Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the jaws-2022 update" 80 : 920-943, 2022
• 53 Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update" 72 : 1938-1956, 2014
• 54 Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update" 67 (67): 2-12, 2009
• 55 Oxman MN, "A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults" 352 : 2271-2284, 2005